Go Pro
→ Jeff Brown and Marc Chaikin's latest AI prediction explained (From Brownstone Research) (Ad)tc pixel
NASDAQ:GNPX

Genprex Q1 2025 Earnings Report

Genprex logo
$8.15 -2.65 (-24.54%)
As of 02:48 PM Eastern
This is a fair market value price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Genprex EPS Results

Actual EPS
-$286.00
Consensus EPS
-$902.00
Beat/Miss
Beat by +$616.00
One Year Ago EPS
N/A

Genprex Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Genprex Announcement Details

Quarter
Q1 2025
Date
5/12/2025
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Genprex's next earnings date is estimated for Wednesday, September 2, 2026, based on past reporting schedules.

Conference Call Resources

Genprex Earnings Headlines

Genprex Announces Reverse Stock Split Amid Nasdaq Compliance Push
July 15 at 4:10 AM  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/genprex-announces-reverse-stock-split-amid-nasdaq-compliance-push?utm_source=marketbeat.com&utm_medium=referral
Genprex Receives a Notice of Allowance from The Canadian Intellectual Property Office for a Patent Claiming the Combination of Reqorsa® Gene Therapy with Either PD-1 or PD-L1 ...
June 22, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/genprex-receives-notice-allowance-canadian-130000079.html
The end may be near for these iconic stocks
Marc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are triggering a historic wealth transfer already underway in 2026. Household names like Intuit (-57%), Boston Scientific (-49%), and Tractor Supply (-40%) are cratering, while lesser-known companies like Sandisk (+573%) and Rackspace (+444%) surge. Chaikin has identified specific stocks he believes investors should sell before they fall further - and the names may surprise you. He's also pinpointing a company tapped as Nvidia's self-driving partner and a potential AI megadeal that could split into three high-growth stocks. Stream his free presentation to get every buy and sell recommendation with no membership or credit card required.tc pixel
July 16 at 1:00 AM  |  Chaikin Analytics (Ad)
Genprex Secures Canadian Patent for Reqorsa Lung Cancer Therapy
June 22, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/genprex-secures-canadian-patent-for-reqorsa-lung-cancer-therapy?utm_source=marketbeat.com&utm_medium=referral
Genprex Receives a Notice of Allowance from The Canadian Intellectual Property Office for a Patent Claiming the Combination of Reqorsa® Gene Therapy with Either PD-1 or PD-L1 Antibodies to Treat Cancer
June 22, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/genprex-receives-a-notice-of-allowance-from-the-canadian-intellectual-property-office-for-a-patent-claiming-the-combination-of-reqorsa-gene-therapy-with-either-pd-1-or-pd-l1-antibodies-to-treat-cancer-302804049.html
Genprex Shareholders Approve Expanded Equity Plan, Reverse Split
June 18, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/genprex-shareholders-approve-expanded-equity-plan-reverse-split?utm_source=marketbeat.com&utm_medium=referral
See More Genprex Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Genprex? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Genprex and other key companies, straight to your email.

About Genprex

Genprex (NASDAQ:GNPX), Inc. is a clinical-stage gene therapy company focused on developing novel, first-in-class treatments for cancer and diabetes. Its proprietary technology employs targeted nanoparticle delivery of therapeutic genes designed to address the underlying genetic drivers of disease. Genprex’s lead oncology candidate, Oncoprex immunogene therapy, is being evaluated for patients with non-small cell lung cancer, with the goal of restoring tumor suppressor function and enhancing response to existing targeted therapies in clinical trials across the United States.

In addition to its oncology pipeline, Genprex is advancing GPTX-203, a gene therapy candidate aimed at improving pancreatic beta-cell function in patients with type 1 diabetes. This preclinical program seeks to deliver genes that support insulin production and glucose regulation, laying the groundwork for future clinical development in metabolic diseases. By leveraging its gene delivery platform, the company aims to expand its pipeline into other oncology and metabolic indications over time.

Headquartered in Austin, Texas, Genprex operates under a management team with deep experience in gene therapy research and biopharmaceutical development. The company collaborates with leading academic and clinical research centers to conduct its studies, ensuring rigorous trial design and patient enrollment. Through these partnerships, Genprex seeks to translate cutting-edge genetic science into transformative therapies for patients with high-unmet medical needs.

View Genprex Profile
Earnings Tools